Trial Profile
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C] ASN002 Following a Single Oral Dose in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2023
Price :
$35
*
At a glance
- Drugs Gusacitinib (Primary)
- Indications Atopic dermatitis; Chronic lymphocytic leukaemia; Myelofibrosis; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Solid tumours
- Focus Pharmacokinetics
- Sponsors Asana BioSciences
- 31 Oct 2018 Status changed from not yet recruiting to completed.
- 28 Aug 2018 New trial record